San Diego-based Viking Therapeutics marked itself as a serious competitor during the weight loss drug market place in February just after revealing promising info from a mid-stage trial of experimental drug VK2735, which recommended it rivaled—and outperformed—Novo and Lilly drugs when provided as a weekly injection and in March the company unv